Carl Zeiss Meditec looks back on successful financial year
Advertisement
With double-digit growth rates in revenue and its operating result, Carl Zeiss Meditec once again grew significantly in the past financial year. The medical technology company even slightly exceeded its revenue forecast for financial year 2011/2012, of EUR 830 - 860 million, with revenue growth of 13.6 percent to EUR 861.9 million (previous year: EUR 758.8 million). In addition to increasing its earnings before interest and tax (EBIT) by 18.7 percent to EUR 122.9 million (previous year: EUR 103.6 million), Carl Zeiss Meditec also further increased its profitability: the EBIT margin rose to 14.3 percent, compared with 13.6 percent the previous year. Earnings per share increased to EUR 0.88 (previous year: EUR 0.82). Cash flow from operating activities rose to EUR 92.1 million (previous year: EUR 33.2 million). As announced, the Supervisory Board and Management Board shall propose to the Annual General Meeting a dividend of EUR 0.40 per share for financial year 2011/2012.
The proportion of employees working in our Research and Development (R&D) department, on the innovations of the future, remains high at around 16 percent. In the reporting year Carl Zeiss Meditec invested 10.8 percent of its revenue in R&D.
Other news from the department business & finance
